Croi Valve

Elkstone first invested in CroiValve’s €8m Series A round in December 2021. The round was led by leading medtech investment syndicates with participation from deep tech investors Atlantic Bridge, SOSV and Boston-based cardiology specialist investors Broadview Ventures. More recently the Company raised a $16m Series B led by the same investor group highlighting the Company’s progress to date and the opportunity ahead of them. 

Having successfully completed European First in Human study, the TANDEM I study, which demonstrated market improvements in patient quality of life metrics, the company now moves on to commence TANDEM II Early Feasibility Study, an FDA-approved, prospective, multicenter study to evaluate the safety and performance of the DUO System in patients with severe or greater symptomatic tricuspid regurgitation (TR).